1)Antithrombotic Trialists'(ATT)Collaboration:Aspirin in the primary and secondary prevention of vascular disease;Collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849-1860, 2009
2)Berger JS, et al:Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease;A meta-analysis of randomized trials. Am Heart J 162:115-124, 2011
3)Fox CS, et al:Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence;A scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 38:1777-1803, 2015
4)Bibbins-Domingo, K:Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer;US Preventive Services Task Force recommendation statement. Ann Intern Med 164:836-845, 2016
5)Ogawa H, et al:Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes;A randomized controlled trial. JAMA 300:2134-2141, 2008
6)島本和明,他:ダイジェスト版—虚血性心疾患の一次予防ガイドライン(2012年改訂版),日本循環器学会,2012 http://www.j-circ.or.jp/guideline/pdf/JCS2012_shimamoto_d.pdf(2017年11月閲覧)
7)堀 正二,他:ダイジェスト版—循環器疾患における抗凝固・抗血小板療法に関するガイドライン(2009年改訂版,2015年10月7日更新版),日本循環器学会,2010 http://www.j-circ.or.jp/guideline/pdf/JCS2009_hori_d.pdf(2017年11月閲覧)
8)Teramoto T, et al:Rationale, design, and baseline data of the Japanese Primary Prevention Project(JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. Am Heart J 159:361-369, 2010
9)Saito Y, et al:Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus;10-year follow-up of a randomized controlled trial. Circulation 135:659-670, 2017